Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma.

Wang, Zhen; Zheng, Wanqun; Chen, Zhen; Wu, Shilun; Chang, Haoxiao; Cai, Ming; Cai, Heping

Wang, Zhen; Zheng, Wanqun; Chen, Zhen; Wu, Shilun; Chang, Haoxiao; Cai, Ming; Cai, Heping.

Afiliação

Wang Z; Department of Pharmacy, Anhui Provincial Children's Hospital, Hefei, China.
Zheng W; Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Chen Z; Department of Pharmacy, The Third People's Hospital of Hefei, Hefei, China.
Wu S; Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
Chang H; China National Clinical Research Center for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Cai M; Department of Pharmacy, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Cai H; Anhui Acupuncture and Moxibustion Clinical Medicine Research Center, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.

Front Oncol ; 12: 1055376, 2022.

Article em En | MEDLINE | ID: mdl-36531056

Palavras-chave

ACO2; hepatocellular carcinoma; immune infiltration; lipidomics; pan-cancer; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google